Annovis Bio presents buntanetap development update, targets Alzheimer’s drug application in 2027
ANVS•Annovis Bio expects symptomatic data from its Phase 3 DUET-AD Alzheimer’s trial in Q1 2027 and targets a symptomatic-treatment NDA that quarter, followed by a disease-modifying NDA in Q1 2028. The trial is fully enrolled with 862 participants; cash totaled $21 million, with no debt.
1. Trial and application timeline
Annovis Bio expects symptomatic data from its Phase 3 DUET-AD Alzheimer’s trial in Q1 2027 and targets an NDA for symptomatic treatment in Q1 2027, followed by a disease-modifying NDA in Q1 2028. The fully enrolled trial has 862 participants receiving buntanetap or placebo over 18 months. The company also said its completed Phase 3 Parkinson’s trial met its endpoints in the per-protocol population, and that it had $21 million in cash and no debt.
